Anti-tumor effects of costunolide on gallbladder cancer and its mechanism

doi:10.3877/cma.j.issn.2095-3232.2020.04.021

Abstract

Abstract:

Objective

To investigate the effect of costunolide (Cos) on the proliferation and invasion of gallbladder cancer cells and its possible mechanism.

Methods

Gallbladder cancer cells were treated with different concentrations of Cos. Cell proliferation, apoptosis, cycle, migration, and changes of related proteins expression were detected with CCK-8, clone formation, flow cytometry, Transwell and Western blot.

Results

The result of CCK-8 showed that the cytoactive in Cos-treated group was inhibited to varying degree and the inhibition was time and dose-dependent. Clone formation experiment showed that the cell clone number in Cos group was significantly less than that in control group with dose-dependent relation. The results of flow cytometry showed that the percentage of apoptosis and proportion of cells in S andG2/M phases increased in Cos group. Western blot test results showed that, as Cos concentration increased, the expression of cyclin A, cyclin B1 decreased gradually, and the expression of p-JNK, apoptosis-related proteins such as cleaved PARP, cleaved caspase-3, cleaved caspase-9, Bax, etc. increased, while the expression of Bcl-2 decreased. Transwell results showed that the number of transmembrane cells decreased with the increase of Cos concentration. Western blot test results showed that, the expression of MMP-2, MMP-9 decreased with the increase of Cos concentration.

Conclusions

Cos can inhibit the proliferation of gallbladder cancer cells, induce cell apoptosis, block cell cycle, and inhibit cell migration in vitro.

Key words: Costunolide, Gallbladder neoplasms, Apoptosis, Cell cycle, Cell migration

Xiaoyu Zhang, Tianyu Zhai, Zhenyu Hei, Di Zhou, Jiandong Wang. Anti-tumor effects of costunolide on gallbladder cancer and its mechanism[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2020, 09(04): 389-394.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2020.04.021

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2020/V09/I04/389

Figures/Tables 4

References 26

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1):7-30.
[2]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[3]	Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer, 2019, 144(8):1941-1953.
[4]	Millimouno FM, Dong J, Yang L, et al. Targeting apoptosis pathways in cancer and perspectives with natural compounds from mother nature[J]. Cancer Prev Res, 2014, 7(11):1081-1107.
[5]	Cragg GM, Newman DJ. Plants as a source of anti-cancer agents[J]. J Ethnopharmacol, 2005, 100(1-2):72-79.
[6]	Chin YW, Balunas MJ, Chai HB, et al. Drug discovery from natural sources[J]. AAPS J, 2006, 8(2):E239-253.
[7]	Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants[J]. Life Sci, 2005, 78(5):431-441.
[8]	Lin X, Peng Z, Su C. Potential anti-cancer activities and mechanisms of costunolide and dehydrocostuslactone[J]. Int J Mol Sci, 2015, 16(5):10888-10906.
[9]	Roy A, Manikkam R. Cytotoxic impact of costunolide isolated from costus speciosus on breast cancer via differential regulation of cell cycle, an in-vitro and in-silico approach[J]. Phytother Res, 2015, 29(10):1532-1539.
[10]	Hua P, Sun M, Zhang G, et al. Costunolide induces apoptosis through generation of ROS and activation of P53 in human esophageal cancer eca-109 cells[J]. J Biochem Mol Toxicol, 2016, 30(9):462-469.
[11]	Hua P, Zhang G, Zhang Y, et al. Costunolide induces G1/S phase arrest and activates mitochondrial-mediated apoptotic pathways in SK-MES 1 human lung squamous carcinoma cells[J]. Oncol Lett, 2016, 11(4):2780-2786.
[12]	Yan Z, Xu T, An Z, et al. Costunolide induces mitochondria-mediated apoptosis in human gastric adenocarcinoma BGC-823 cells[J]. BMC Complement Altern Med, 2019, 19(1):151.
[13]	Kumar A, Singh UK, Kini SG, et al. JNK pathway signaling: a novel and smarter therapeutic targets for various biological diseases[J]. Future Med Chem, 2015, 7(15):2065-2086.
[14]	Qin J, Zhou J, Teng L, et al. MicroRNA-10b promotes apoptosis via JNK pathway in clear cell renal cell carcinoma[J]. Nephron, 2018, 139(2):172-180.
[15]	Shi X, Jiang B, Liu H, et al. ZCCHC9 promotes proliferation and invasion of lung cancer through regulating the JNK pathway[J].J Cell Biochem, 2019, 120(6):10596-10604.
[16]	Peng Z, Wang Y, Fan J, et al. Costunolide and dehydrocostuslactone combination treatment inhibit breast cancer by inducing cell cycle arrest and apoptosis through c-Myc/p53 and AKT/14-3-3 pathway[J]. Sci Rep, 2017(7):41254.
[17]	Kim JH, Yang YI, Lee KT, et al. Costunolide induces apoptosis in human endometriotic cells through inhibition of the prosurvival Akt and nuclear factor kappa B signaling pathway[J]. Biol Pharm Bull, 2011, 34(4):580-585.
[18]	Cai H, He X, Yang C. Costunolide promotes imatinib-induced apoptosis in chronic myeloid leukemia cells via the Bcr/Abl-Stat5 pathway[J]. Phytother Res, 2018, 32(9):1764-1769.
[19]	Dong GZ, Shim AR, Hyeon JS, et al. Inhibition of Wnt/β-Catenin pathway by dehydrocostus lactone and costunolide in colon cancer cells[J]. Phytother Res, 2015, 29(5):680-686.
[20]	Collins K, Jacks T, Pavletich NP. The cell cycle and cancer[J]. Proc Natl Acad Sci U S A, 1997, 94(7):2776-2778.
[21]	Graña X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)[J]. Oncogene, 1995, 11(2):211-219.
[22]	Kastan MB, Canman CE, Leonard CJ. P53, cell cycle control and apoptosis: implications for cancer[J]. Cancer Metastasis Rev, 1995, 14(1):3-15.
[23]	Pavletich NP. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors[J]. J Mol Biol, 1999, 287(5):821-828.
[24]	Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression[J]. Nat Rev Cancer, 2002, 2(3):161-174.
[25]	Nelson AR, Fingleton B, Rothenberg ML, et al. Matrix metalloproteinases: biologic activity and clinical implications[J].J Clin Oncol, 2000, 18(5):1135-1149.
[26]	Davidson B, Goldberg I, Gotlieb WH, et al. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma[J]. Clin Exp Metastasis, 1999, 17(10):799-808.

Please choose a citation manager

Content to export